News

We continue to participate in protocols for the treatment of inflammatory bowel diseases: a portfolio of new studies on Crohn's disease and ulcerative colitis.

Participation in a clinical study of a new biological therapy for the treatment of Covid-19 infection in children is proposed.

We were invited to participate in a new clinical trial conducted by the pharmaceutical company Bayer: a new anticoagulant for the treatment of atrial fibrillation.

The selection to participate in a randomized trial to assess the tolerability, safety, and immunogenicity of a new influenza vaccine in children aged 6 months to 17 years has been successfully completed in our Site.